Montgomery

Researchers are evaluating treatment preferences and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride XT therapy. This observational study aims to understand patient experiences with this therapy over time to help inform future treatment approaches. Participants in this study are adults aged 18 years or older with a confirmed diagnosis of schizophrenia who have recently received a prescription for XT therapy and plan to start the treatment. The study observes participants using this therapy according to the product label without altering their prescribed regimen. During the study, participants will provide information about their medication preference and treatment satisfaction through questionnaires at baseline, Month 1, Month 3, and Month 6. Additional data collected include treatment plans, dose changes, concomitant medications, reasons for discontinuation, and baseline clinical and demographic characteristics. Participants will use electronic devices or paper records to report outcomes, and the study will continue until May 2029.